The first batches of drugs manufactured by the new plant will be distributed in Switzerland and the European Union within two years.
Keystone
The pharmaceutical giant Novartis has announced plans to invest CHF90 million ($91.5 million) over three years on a production site for cell and gene therapies. The goal is to enable new treatments to be delivered in Europe.
The expansion will take place at the company’s Stein site in Aargau. As a first step, Novartis plans to create 260 new jobs and says there is potential to raise that number to 450 by 2021. Last year the company announced plans to slash 500 jobs at its Basel headquarters, but said at the time that it wanted to create 350 new positions, mainly in its biotech business.
The first batches of drugs manufactured by the new plant will be distributed in Switzerland and the European Union within two years, Novartis said in a statement on Monday.
“This investment illustrates the changes the sector is undergoing,” said Matthias Leuenberger, Head of Switzerland at Novartis. “As we invest in new highly specialised technologies, the importance of some traditional areas will diminish,” he said.
The announcement of the investment in Stein comes after the European Commission approved the company’s Kymriah cell therapyExternal link for the treatment of acute B-cell lymphoblastic leukemia in children and young adults up to 25 years.
Novartis already operates a plant in the US in Morris Plains, New Jersey, that specialises in the production of cell and gene therapies.
More
More
Novartis to shed 500 jobs in Basel
This content was published on
The Swiss pharmaceutical giant Novartis has announced that it plans to cut 500 jobs at its Basel headquarters in Switzerland over the next 18 months.
In Switzerland more people are being referred to electrical therapies or psychedelic-assisted psychotherapy. Are there similar approaches where you live?
Living longer: What do you think about the longevity trend?
The longevity market is booming thanks in part to advances in the science of ageing. What do you think of the idea of significantly extending human lifespan?
This content was published on
Primary school children in the Swiss canton of Nidwalden will not be allowed to use mobile phones and other electronic devices..
This content was published on
Switzerland has increased maximum possible output from hydropower by 43 megawatts compared to last year, according to the Swiss energy ministry.
SWISS cancels Tel Aviv flights after Ben Gurion airport missile attack
This content was published on
After a missile landed near Tel Aviv’s Ben-Gurion Airport, Swiss International Airlines (SWISS) cancelled its flight from Zurich to Tel Aviv on Sunday.
Swiss foreign minister rejects mandatory referendum for EU deals
This content was published on
Swiss Foreign Minister Ignazio Cassis defended the government’s decision to make EU deals subject to an optional rather than a mandatory referendum.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Novartis: The making of a pharma giant
This content was published on
The company formed when Ciba Geigy and Sandoz merged and analysts say it’s a big success. The merger cost around 10,000 jobs but in the long-run more were created. The current CEO concedes that the merger also meant the loss of the Ciba corporate identity. Novartis’ profits shrank by a third in 2015, partly because…
This content was published on
The status of Novartis as a leading Big Pharma company is beyond doubt. But after five difficult years, critical choices about assets are looming.
Swiss pharma suspected of delaying generic competition
This content was published on
The United States Food and Drug Administration (FDA) lists Novartis and Roche among drug-makers suspected of hindering generic competition.
Export growth increasingly depends on pharmaceuticals
This content was published on
Swiss exports hit a record CHF210 billion ($211 billion) last year and the pharmaceutical sector was one of the big drivers.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.